BR112017028557A2 - total synthesis of shishijimycin a and analogues of this - Google Patents

total synthesis of shishijimycin a and analogues of this

Info

Publication number
BR112017028557A2
BR112017028557A2 BR112017028557A BR112017028557A BR112017028557A2 BR 112017028557 A2 BR112017028557 A2 BR 112017028557A2 BR 112017028557 A BR112017028557 A BR 112017028557A BR 112017028557 A BR112017028557 A BR 112017028557A BR 112017028557 A2 BR112017028557 A2 BR 112017028557A2
Authority
BR
Brazil
Prior art keywords
shishijimycin
analogues
present disclosure
total synthesis
provides
Prior art date
Application number
BR112017028557A
Other languages
Portuguese (pt)
Inventor
N Pitsinos Emmanouil
Woods James
C Nicolaou Kyriacos
Li Ruofan
Sohn Te-Ik
Lu Zhaoyong
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of BR112017028557A2 publication Critical patent/BR112017028557A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

num aspecto, a presente divulgação prove análogos de shishijimicina de fórmula: em que as variáveis são definidas conforme este documento. em outro as-pecto, a presente divulgação também prove métodos de preparo dos compostos aqui descritos. noutro aspecto, a presente divulgação também prove composições farma-cêuticas e métodos de utilização dos compostos divulgados neste documento. além disso, também são providos conjugados de anticorpo-droga dos compostos.In one aspect, the present disclosure provides shishijimycin analogs of formula: wherein the variables are defined herein. in another aspect, the present disclosure also provides methods of preparing the compounds described herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of using the compounds disclosed herein. In addition, antibody-drug conjugates of the compounds are also provided.

BR112017028557A 2015-06-29 2016-06-29 total synthesis of shishijimycin a and analogues of this BR112017028557A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186191P 2015-06-29 2015-06-29
PCT/US2016/040047 WO2017004172A1 (en) 2015-06-29 2016-06-29 Total synthesis of shishijimicin a and analogs thereof

Publications (1)

Publication Number Publication Date
BR112017028557A2 true BR112017028557A2 (en) 2018-09-04

Family

ID=57609044

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028557A BR112017028557A2 (en) 2015-06-29 2016-06-29 total synthesis of shishijimycin a and analogues of this

Country Status (19)

Country Link
US (1) US10590158B2 (en)
EP (1) EP3313389A1 (en)
JP (1) JP2018525346A (en)
KR (1) KR20180053294A (en)
CN (1) CN108348489A (en)
AR (1) AR105193A1 (en)
AU (1) AU2016286071A1 (en)
BR (1) BR112017028557A2 (en)
CA (1) CA2990206A1 (en)
CL (1) CL2017003500A1 (en)
HK (1) HK1254923A1 (en)
IL (1) IL256345A (en)
MA (1) MA42273A (en)
MX (1) MX2017016885A (en)
PE (1) PE20180658A1 (en)
PH (1) PH12018500014A1 (en)
RU (1) RU2018102808A (en)
TW (1) TW201713634A (en)
WO (1) WO2017004172A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357785B (en) * 2019-07-26 2020-03-24 东莞市领创环保材料科技有限公司 Preparation method of cyanate ester resin plasticizer
CN115197188B (en) * 2021-04-12 2023-12-26 南开大学 Sesquiterpene hydroquinone compound with pentacyclic skeleton and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5261586A (en) * 1992-03-26 1993-11-16 Chen Jen Fu Yarn feeding device with a guiding flange
US5550246A (en) * 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
JP2003238584A (en) * 2002-02-08 2003-08-27 Yamanouchi Pharmaceut Co Ltd New enediyne compound
AR048098A1 (en) * 2004-03-15 2006-03-29 Wyeth Corp CALIQUEAMYCIN CONJUGATES
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules

Also Published As

Publication number Publication date
US20180327439A1 (en) 2018-11-15
HK1254923A1 (en) 2019-08-02
PE20180658A1 (en) 2018-04-17
WO2017004172A8 (en) 2018-01-11
CN108348489A (en) 2018-07-31
US10590158B2 (en) 2020-03-17
RU2018102808A3 (en) 2020-04-30
AU2016286071A8 (en) 2019-08-08
AU2016286071A1 (en) 2018-02-01
TW201713634A (en) 2017-04-16
IL256345A (en) 2018-02-28
EP3313389A1 (en) 2018-05-02
CA2990206A1 (en) 2017-01-05
MA42273A (en) 2018-05-02
KR20180053294A (en) 2018-05-21
WO2017004172A1 (en) 2017-01-05
JP2018525346A (en) 2018-09-06
PH12018500014A1 (en) 2018-07-09
CL2017003500A1 (en) 2018-04-27
MX2017016885A (en) 2018-09-06
AR105193A1 (en) 2017-09-13
RU2018102808A (en) 2019-07-30

Similar Documents

Publication Publication Date Title
CY1124239T1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CY1123475T1 (en) LYSINE-1-SPECIFIC INHIBITORS
CY1120480T1 (en) PYRAZOLOPYRIMIDINE COMPOUNDS
BR112017018305A2 (en) deacetoxytubulisine h and analogs thereof
BR112018003812A2 (en) heteroaryl compounds as irak inhibitors and their uses
BR112016029333A2 (en) synthesis of polycyclic carbamoylpyridone compounds
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
BR112017001334A2 (en) imidazopyridazine compounds, their use and pharmaceutical composition comprising them
CY1122441T1 (en) NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATIONS, THEIR PREPARATION AND THERAPEUTIC USE
BR112016017747A2 (en) POST-NERVE INJURY REHABILITATION EFFECT ENHANCEMENT AGENT COMPRISING ALKYL ETHER OR SALT DERIVATIVES
EA201790046A1 (en) BENZOXAZINOUS AMIDES AS MODELS OF MINERALOCORTICOID RECEPTOR MODULATORS
BR112012031340A2 (en) cyanoquinoline derivatives
JO3372B1 (en) 5-benzylisoquinoleine derivatives for the treatment of cardiovascular diseases
CY1122381T1 (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBHTA INHIBITORS
BR112017000584A2 (en) aldosterone synthase inhibitors
DOP2016000293A (en) DERIVATIVES OF DIHETEROCICLO LINKED TO CYCLALKYL
EA201700356A1 (en) NEW CYCLOPROPANBENZOFURANILPYRIDOPYRAZINDIONS
CY1122375T1 (en) TETRAHYDROFURAN-CONDENSED AMINOHYDROTHIAZINE ANALOGS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
EA201690294A1 (en) NEW CONNECTIONS AND THEIR APPLICATION FOR OBTAINING TAU-VISUALIZING AGENTS AND TAU-VISUALIZING COMPOSITIONS
BR112017028557A2 (en) total synthesis of shishijimycin a and analogues of this
BR112018007673A2 (en) epothilone analogs, synthesis methods, treatment methods and drug conjugates thereof.
MX2018015269A (en) Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof.
EA201591449A1 (en) METHODS OF OBTAINING TREATMENT COMPOSITIONS
UY32448A (en) DERIVATIVES OF 3-BENZOFURANIL-INDOL-2-ONA-3-ACETAMIDOPIPERAZINAS REPLACED, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
BR112017013194A2 (en) total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.